Apolipoprotein E genotyping in Alzheimer's disease-Reference-Cited by-同舟云学术

Apolipoprotein E genotyping in Alzheimer's disease

Published:1996-06 Issue:9017 Volume:347 Page:1775-1776
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

McKeith G,Morris C.M,Lovestone Simon,Wilcock Gordon,Rossor Martin,Cayton Harry,Ragan Ian,Humphries S,Betteridge D.J,Durrington P.N,Galton D.J,Nicholls P

Publisher

Elsevier BV

Subject

General Medicine

Reference9 articles.

1. Apolipoprotein E genotyping in Alzheimer's disease;National Institute on Aging/Alzheimer's Association Working Group;Lancet,1996

2. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT);McKeith;Br J Psychiatry,1994

3. Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias;Morris;J Neurol Transm,1996

4. Ig McKeith, D. Galasko, K. Kosaka, et al., Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the CDLB International Workshop, Neurology ((in press)).

5. Apolipoprotein E genotyping in Alzheimer's Disease;National Institute of Aging/Alzheimer's Association Working Group;Lancet,1996

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Diagnosis of Channelopathies, Epilepsies, Migraine, Stroke and Dementias;European Handbook of Neurological Management;2011-09-21

2. EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias;European Journal of Neurology;2010-03-09

3. The personalised is political;The Politics of Personalised Medicine;2004-12-02

4. Disappointment and disclosure in the pharmacogenetic clinic;The Politics of Personalised Medicine;2004-12-02

5. The fourth hurdle – cost-effectiveness and the funding of pharmacogenetics;The Politics of Personalised Medicine;2004-12-02